Evoke Pharma
EVOK66
$4.23arrow_drop_down1.85%-$0.08
Penny Stock
EVOK66
$4.23
arrow_drop_down1.85%Performance History
| Key Stats | |
|---|---|
| Open | $4.17 |
| Prev. Close | $4.19 |
| EPS | 116.88 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $3.53M |
| LOW | HIGH | |
|---|---|---|
| Day Range | 4.12 | 4.38 |
| 52 Week Range | 3.54 | 18.60 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | 116.88 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Evoke Pharma (EVOK)
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- CEO
- Mr. David A. Gonyer R.Ph.
- Headquarters
- Solana Beach
- Employees
- 4
- Exchange
- NASDAQ
Keep an eye on Evoke Pharma
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Evoke Pharma 's (EVOK) price per share?
The current price per share for Evoke Pharma (EVOK) is $4.23. The stock has seen a price change of -$0.08 recently, indicating a -1.86% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Evoke Pharma (EVOK)?
For Evoke Pharma (EVOK), the 52-week high is $18.6, which is 339.72% from the current price. The 52-week low is $3.54, the current price is 19.49% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Evoke Pharma (EVOK) a growth stock?
Evoke Pharma (EVOK) has shown an average price growth of 0.41% over the past three years. It has received a score of -2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Evoke Pharma as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Evoke Pharma (EVOK) stock price performance year to date (YTD)?
As of the latest data, Evoke Pharma (EVOK) has a year-to-date price change of -65.78%. Over the past month, the stock has experienced a price change of -23.78%. Over the last three months, the change has been -33.26%. Over the past six months, the figure is -43.15%. Looking at a longer horizon, the five-year price change stands at -96.97%.
help
Is Evoke Pharma (EVOK) a profitable company?
Evoke Pharma (EVOK) has a net income of -$7.79M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -47.96% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $4.98M. Operating income is noted at -$7.43M. Furthermore, the EBITDA is $0.
help
What is the market capitalization of Evoke Pharma (EVOK)?
Evoke Pharma (EVOK) has a market capitalization of $3.53M. The average daily trading volume is 11.83K, indicating the stock's liquidity and investor engagement.
News
FIERCE PHARMA MARKETING AWARDS
HEALTH UNION SOCIAL HEALTH AWARDS
DIGITAL PHARMA EAST
9/12/2024Questex’s Fierce Pharma Announces the 2024 Fierce Pharma Marketing Awards Winners
EVOKE PHARMA
GIMOTI
DIABETIC GASTROPARESIS
FINANCIAL RESULTS
8/13/2024Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
DIRECTORS AND OFFICERS
HEALTH
PRODUCT / SERVICES ANNOUNCEMENT
PARTNERSHIPS
6/17/2024Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
CALENDAR OF EVENTS
5/16/2024Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference
EARNINGS RELEASES AND OPERATING RESULTS
CONFERENCE CALLS/ WEBCASTS
5/14/2024Evoke Pharma Reports First Quarter 2024 Financial Results
HEALTH
CONFERENCE CALLS/ WEBCASTS
4/17/2024Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications